Table 2.
Py apig3pdh(−) and Py apig3pat(−) sporozoites act as immunogens, protecting mice from a wildtype sporozoite challenge.
| Parasite Typea | Primeb | Boost (6 weeks)b |
Challenge (6 weeks after boost)c |
Repeat #1 #BALB/cJ mice patentd |
Repeat #2 #BALB/cJ mice patentd |
Repeat #3 #BALB/cJ mice patentd |
|---|---|---|---|---|---|---|
| Py 17XNL (WT control) | n/a | n/a | 10,000 | 5/5 | 5/5 | 5/5 |
| Py apig3pdh(−) (Clone 1) | 10,000 | 10,000 | 10,000 | 0/5 | 0/5 | 0/5 |
| (Clone 2) | 10,000 | 10,000 | 10,000 | 0/5 | 0/5 | 0/5 |
| Py apig3pat(−) (Clone 1) | 10,000 | 10,000 | 10,000 | 0/5 | 0/5 | 0/5 |
| (Clone 2) | 10,000 | 10,000 | 10,000 | 0/5 | 0/5 | 0/5 |
Control mice were injected with salivary gland lysate from uninfected mosquitoes for the prime and boost.
10,000 salivary gland sporozoites were injected intravenously for both the prime and boost. For controls, mice were injected with an equivalent amount of mosquito salivary gland extract from mosquitoes that received and uninfectious blood meal.
10,000 Py 17XNL wildtype salivary gland sporozoites were injected intravenously for the challenge.
Giemsa-stained thin blood smears were analyzed for patency from days three to fourteen after challenge. No mice immunized with Py apig3pdh(−) and Py apig3pat(−) sporozoites became patent.